Raloxifene
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Raloxifene and local guidelines before prescribing.
SERM
Mechanism
Selective oestrogen receptor modulator.
Uses
Postmenopausal osteoporosis.
Dosing
- Raloxifene | 60 mg orally daily. Reduces vertebral fractures only. VTE risk.
Endocrinology: Bone Medicine
Side effects
Hot flushes, leg cramps, VTE, stroke risk.
Interactions
Cholestyramine reduces absorption; warfarin effect lowers.
Contraindications and cautions
VTE history, liver disease
Monitoring
Bone density, VTE signs
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in severe renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Reduces vertebral not hip fracture; lowers breast cancer risk.
More from the textbook: uses, cautions and other points
- Options for high-risk women - earlier and more frequent screening (annual MRI from 30 for BRCA carriers, with mammography from 40), chemoprevention (tamoxifen or raloxifene before menopause/after; anastrozole after menopause), risk-reducing mastectomy (reduces risk by about 90% or more) and risk-reducing salpingo-oophorectomy.
Surgey: Breast and endocrine surgery - Raloxifene (SERM) - postmenopausal spinal osteoporosis; VTE risk , hot flushes; reduces breast cancer risk.
Endocrine: Anatomy Physiology and Pharmacology - Antiresorptive: Slow osteoclasts down to reduce bone loss - bisphosphonates, denosumab, HRT, raloxifene.
Endocrinology: Bone Medicine - Thrombosis | Combined pill , oral HRT , tamoxifen and raloxifene, thalidomide and lenalidomide , ESAs, JAK inhibitors, asparaginase, tranexamic acid (if pre-existing clot risk), testosterone (via polycythaemia), antipsychotics, steroids, ponatinib
Haematology: Anatomy Physiology and Pharmacology - HRT and raloxifene | Oestrogen (receptor) effects reduce resorption | HRT — younger postmenopausal women; raloxifene (SERM) — VTE risk, reduces breast cancer
Rheumatology Anatomy Physiology Pharmacology
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Bone Medicine (2 mentions)
- Haematology: Anatomy Physiology and Pharmacology (1 mention)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Surgey: Breast and endocrine surgery (1 mention)